JP2000143531A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2000143531A5 JP2000143531A5 JP1999227108A JP22710899A JP2000143531A5 JP 2000143531 A5 JP2000143531 A5 JP 2000143531A5 JP 1999227108 A JP1999227108 A JP 1999227108A JP 22710899 A JP22710899 A JP 22710899A JP 2000143531 A5 JP2000143531 A5 JP 2000143531A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid residue
- group
- residue selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000539 amino acid group Chemical group 0.000 description 7
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 3
- 241000024188 Andala Species 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- 125000000534 N(2)-L-lysino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C([H])([H])C(C([H])([H])N([H])[H])([H])[H] 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
Description
【００１１】
【化３】
Ｘ−Ａ−Ｄ−Ｅ−Ｇ−Ｊ−Ｌ−Ｍ−Pro−Ｑ−Ｙ （Ｉ）
（式中、Ｘは水素、ＣＨ3−ＣＯ−およびＣＨ3−ＣＯ−Ｌys−からなる群から選ばれる基、ＡはＳerおよびＴhrから選ばれるアミノ酸残基、ＤはＩle、ＶalおよびＬeuからなる群から選ばれるアミノ酸残基、ＥはＬysおよびＡrgから選ばれるアミノ酸残基、ＧはＩle、ＶalおよびＬeuからなる群から選ばれるアミノ酸残基、ＪはＧlyおよびＡlaから選ばれるアミノ酸残基、ＬはＩle、ＶalおよびＬeuからなる群から選ばれるアミノ酸残基、ＭはＧlyおよびＡlaから選ばれるアミノ酸残基、ＱはＧly、ＡlaおよびＧly−Ｌys−Ｌys−Ｇlyからなる群から選ばれるアミノ酸残基またはペプチド残基、並びにＹは−ＯＨまたは−ＮＨ2を示す。）
で表されるペプチド、配列番号８で表されるペプチド、配列番号９で表されるペプチド、配列番号１０で表されるペプチド、配列番号１１で表されるペプチド、配列番号１２で表されるペプチド、配列番号１３で表されるペプチド、配列番号１４で表されるペプチドおよびそれらの塩から選ばれる少なくとも１種を基材に固定化してなることを特徴とする神経再生用材料である。
[0011]
Embedded image
XADEGGJLMM-Pro-QY (I)
(Where X is hydrogen, a group selected from the group consisting of CH 3 —CO— and CH 3 —CO-Lys—, A is an amino acid residue selected from Ser and Thr, and D is Ile, Val and Leu. E is an amino acid residue selected from the group consisting of Lys and Arg; G is an amino acid residue selected from the group consisting of Ile, Val and Leu; J is an amino acid residue selected from Gly and Ala; Is an amino acid residue selected from the group consisting of Ile, Val and Leu, M is an amino acid residue selected from Gly and Ala, Q is an amino acid residue selected from the group consisting of Gly, Ala and Gly-Lys-Lys-Gly or a peptide residue, and Y represents an -OH or -NH 2.)
Peptide represented by SEQ ID NO: 8, peptide represented by SEQ ID NO: 9, peptide represented by SEQ ID NO: 10, peptide represented by SEQ ID NO: 11, peptide represented by SEQ ID NO: 12 , peptide represented by SEQ ID NO: 13, a nerve regeneration material, wherein Rukoto such at least one kind of immobilized on a substrate selected from peptides and salts thereof represented by SEQ ID NO: 14.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP22710899A JP4410879B2 (en) | 1998-09-09 | 1999-08-11 | Nerve regeneration material |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP27049898 | 1998-09-09 | ||
| JP10-270498 | 1998-09-09 | ||
| JP22710899A JP4410879B2 (en) | 1998-09-09 | 1999-08-11 | Nerve regeneration material |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2000143531A JP2000143531A (en) | 2000-05-23 |
| JP2000143531A5 true JP2000143531A5 (en) | 2006-05-18 |
| JP4410879B2 JP4410879B2 (en) | 2010-02-03 |
Family
ID=26527515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP22710899A Expired - Fee Related JP4410879B2 (en) | 1998-09-09 | 1999-08-11 | Nerve regeneration material |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4410879B2 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002369877A (en) * | 2001-06-14 | 2002-12-24 | Japan Science & Technology Corp | Nerve reconstructive biomaterial and method of manufacturing the same |
| JP4592295B2 (en) * | 2004-01-23 | 2010-12-01 | 株式会社ニッシン | Dental alginate impression material composition |
| ES2293753B1 (en) * | 2004-04-28 | 2009-03-16 | Lipotec, S.A. | USE OF XIKVAV PEPTIDES IN PREPARATION OF COSMETIC COMPOSITIONS TO IMPROVE SKIN FIRMING THROUGH THE INCREASE OF CELLULAR ADHESION. |
| JP5131745B2 (en) * | 2007-09-13 | 2013-01-30 | 独立行政法人国立循環器病研究センター | Nerve guide tube |
| CN107530475B (en) | 2015-04-15 | 2021-06-08 | 新泽西州立拉特格斯大学 | Biocompatible implants for nerve regeneration and methods of use thereof |
-
1999
- 1999-08-11 JP JP22710899A patent/JP4410879B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002536960A5 (en) | ||
| IL163066A (en) | Ligands for the zcytor17 receptor | |
| JP2005505579A5 (en) | ||
| CA2551182A1 (en) | Novel kappa receptor selective opioid peptides | |
| MY123740A (en) | Il-13 receptor polypeptide | |
| CA2125174A1 (en) | Novel polypeptides for promoting cell attachment | |
| WO2005051998A3 (en) | Antibodies binding to a c-terminal fragment of apolipoprotein e | |
| WO1996016982A3 (en) | Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof | |
| EP2314604A3 (en) | Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof | |
| WO2001081376A3 (en) | Apo-ai/aii peptide derivatives | |
| DK1114156T3 (en) | Transforming growth factor Beta-9 (ZTGFSS9) from mammals | |
| JP2000143531A5 (en) | ||
| JP2006514820A5 (en) | ||
| JP2002517193A5 (en) | ||
| JP2006503088A5 (en) | ||
| WO2001027136A3 (en) | Peptides which stimulate the immune response and tissue regeneration | |
| JP2002533115A5 (en) | ||
| JP2003334088A5 (en) | ||
| JP2005501508A5 (en) | ||
| JP2005516996A5 (en) | ||
| AU2957099A (en) | Novel physiologically active peptides and utilization thereof | |
| AU2865801A (en) | Therapeutic peptides | |
| JP2002522355A5 (en) | ||
| CA2399378A1 (en) | Sodium-independent small neutral amino acid transporters transporting l- and d-amino acids and genes thereof | |
| JP2006510360A5 (en) |